Clinical Trials Logo

Clinical Trial Summary

Omacor is likely to decrease lipid parameters in HIV infected subjects. In these subjects the lipid are decrease due to HAART treatment


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00598910
Study type Interventional
Source Solvay Pharmaceuticals
Contact
Status Terminated
Phase Phase 4
Start date August 2007
Completion date March 2009